Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares

DMAA·NASDAQ

$10.61

+0.094%
Financial ServicesShell Companies

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

At a Glance

Live Snapshot
Market Cap$357.74M
EPS0.1900
P/E Ratio55.84
Earnings Date

dmaa

Total Current Liabilities

Last Annual Value

376.17K

3-Year CAGR

679%

5-Year CAGR

243%

10-Year CAGR

85%

Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares Competitors Analysis of Total Current Liabilities

DMAA · NASDAQ
CompanyTotal Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
376.17K
N/AN/AN/A 
304.59K
N/AN/AN/A
60.48K
N/A-52.0%N/A
698.20K
N/AN/AN/A
117.54K
N/AN/AN/A
1.11M
N/AN/AN/A
40.10K
N/AN/AN/A
733.35K
N/AN/AN/A
733.35K
N/AN/AN/A
Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares Fair Value Envelope

DMAA · NASDAQ

Our analysis suggests that DMAA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.61, this represents a potential HIDDEN relative to our calculated worth for Drugs Made In America Acquisition Corp. Ordinary Shares.

Intrinsic Value
Current Price: $10.61